Trials / Approved For Marketing
Approved For MarketingNCT01160250
A Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
A Single-Arm, Open-Label, Expanded Access Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, non-comparative, multicenter, expanded access study of Vismodegib (GDC-0449) in patients with locally advanced basal cell carcinoma (BCC) or metastatic BCC (mBCC) who are otherwise without satisfactory treatment options.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | vismodegib (GDC-0449) | Oral repeating dose |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2012-04-01
- Completion
- 2012-04-01
- First posted
- 2010-07-12
- Last updated
- 2015-08-06
Locations
11 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01160250. Inclusion in this directory is not an endorsement.